drug store, pharmacy, chain drug store, drugstore, community pharmacy, drug chain, retail pharmacy




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Week of   

























































































































































































































































Week of Mon, Mar 17th, 2014

Actavis readies Daytrana generic following patent settlement

Actavis plc has entered into an agreement with Noven Pharmaceuticals Inc. to settle patent litigation related to Actavis' generic version of Daytrana.

Sprite nets new limited-time flavor with LeBron James

Sprite has teamed up with basketball superstar LeBron James to create a new limited-edition flavor.

GoGargle! named Best New Product at ECRM event

GoGargle!, an effervescent salt gargle to soothe and moisturize dry and irritated throats, was chosen by retailers as Best New Product at the 2014 ECRM Cough/Cold, Analgesics and Allergy Convention.

Pringles introduces tortilla chips

Pringles has expanded its savory snack lineup with its first-ever tortilla chip, Pringles Tortillas.

Pernix names senior VP of sales, marketing

Rick Shalaby has joined Pernix Therapeutics Holdings Inc. as senior vice president of sales and marketing.

Fannie May Confections recalls some assorted chocolates

Fannie May Confections Brands Inc. is voluntarily recalling 19 units of its 14-ounce rectangular box of spring wrapped assorted chocolates because of a labeling issue.

American Greetings extends line with pop-up cards

American Greetings Corp. has rolled out Blown Away, a new collection of pop-up birthday cards featuring lights and sound.

Bristol-Myers, Pfizer gain FDA approval for Eliquis

Bristol-Myers Squibb Co. and Pfizer Inc. have received Food and Drug Administration approval for their Supplemental New Drug Application (sNDA) for Eliquis (apixaban), indicated to treat prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

Advertisement